Garcinia mangostana
PreclinicalSmall molecule
Garcinia mangostana is one of 14 small molecule programs targeting Chronic Periodontitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Periodontitis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Zocor
OOrganon and Co
Approved
Minocin
TTriax
Approved
Singulair
OOrganon and Co
Approved
Glucophage
EMD SeronoApproved
Fosamax
OOrganon and Co
Approved
Verazinc
FFakultas Kedokteran Universitas Indonesia
Preclinical
Lactobacillus Reuteri
TTulane University School of Medicine
Preclinical
Garcinia mangostana
MMeenakshi Ammal Dental College and Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Garcinia mangostana. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details